9 research outputs found
Labeling Preferences of Diazirines with Protein Biomolecules
Diazirines are widely used in photoaffinity labeling (PAL) to trap non-covalent interactions with biomolecules. However, design and interpretation of PAL experiments is challenging without a molecular understanding of the reactivity of diazirines with protein biomolecules. Here, we report a systematic evaluation of the labeling preferences of alkyl and aryl diazirines with individual amino acids, single proteins, and in the whole cell proteome. We find that aryl-fluorodiazirines react primarily through a carbene intermediate, while alkyl diazirines generate a reactive alkyl diazo intermediate on route to the carbene. The generation of a reactive diazo intermediate leads to preferential labeling of acidic amino acids in a pH-dependent manner. From a survey of 32 alkyl diazirine probes, we use this reactivity profile to rationalize why these probes preferentially enrich highly acidic proteins or those embedded in membranes and why probes with a net positive-charge tend to produce higher labeling yields. These results indicate that alkyl diazirines are an especially effective chemistry for surveying the membrane proteome, and will facilitate probe design and interpretation of biomolecular labeling experiments with diazirines.</p
Protein Electrophile-Binding Motifs: Lysine-Rich Proteins Are Preferential Targets of Quinones
Quinones represent an important class of endogenous compounds such as
neurotransmitters and coenzyme Q10, electrophilic xenobiotics, and
environmental toxicants that have known reactivity based on their ability to
redox cycle and generate oxidative stress, as well as to alkylate target
proteins. It is likely that topological, chemical, and physical features
combine to determine which proteins become targets for chemical adduction.
Chemical-induced post-translational modification of certain critical proteins
causes a change in structure/function that contributes to the toxicological
response to chemical exposure. In this study, we have identified a number of
proteins that are modified by quinone-thioethers after administration of
2-(glutathion-S-yl)HQ. Parallel one-dimensional gel electrophoresis
was performed, and the Coomassie-stained gel was aligned with the
corresponding Western blot, which was probed for adductions. Immunopositive
bands were then subjected to trypsin digestion and analyzed via liquid
chromatography/tandem mass spectrometry. The proteins that were subsequently
identified contained a higher than average (9.7 versus 5.5%) lysine content
and numerous stretches of lysine run-ons, which is a presumed electrophile
binding motif. Approximately 50% of these proteins have also been identified
as targets for electrophilic adduction by a diverse group of chemicals by
other investigators, implying overlapping electrophile adductomes. By
identifying a motif targeted by electrophiles it becomes possible to make
predictions of proteins that may be targeted for adduction and possible sites
on these proteins that are adducted. An understanding of proteins targeted for
adduction is essential to unraveling the toxicity produced by these
electrophiles
The Frequency of 1,4-Benzoquinone-Lysine Adducts in Cytochrome c Correlate with Defects in Apoptosome Activation
Electrophile-mediated post-translational modifications (PTMs) are known to cause tissue toxicities and disease progression. These effects are mediated via site-specific modifications and structural disruptions associated with such modifications. 1,4-Benzoquinone (BQ) and its quinone-thioether metabolites are electrophiles that elicit their toxicity via protein arylation and the generation of reactive oxygen species. Site-specific BQ-lysine adducts are found on residues in cytochrome c that are necessary for protein-protein interactions, and these adducts contribute to interferences in its ability to facilitate apoptosome formation. To further characterize the structural and functional impact of these BQ-mediated PTMs, the original mixture of BQ-adducted cytochrome c was fractionated by liquid isoelectric focusing to provide various fractions of BQ-adducted cytochrome c species devoid of the native protein. The fractionation process separates samples based on their isoelectric point (pI), and because BQ adducts form predominantly on lysine residues, increased numbers of BQ adducts on cytochrome c correlate with a lower protein pI. Each fraction was analyzed for structural changes, and each was also assayed for the ability to support apoptosome-mediated activation of caspase-3. Circular dichroism revealed that several of the BQ-adducted cytochrome c species maintained a slightly more rigid structure in comparison to native cytochrome c. BQ-adducted cytochrome c also failed to activate caspase-3, with increasing numbers of BQ-lysine adducts corresponding to a greater inability to activate the apoptosome. In summary, the specific site of the BQ-lysine adducts, and the nature of the adduct, are important determinants of the subsequent structural changes to cytochrome c. In particular, adducts at sites necessary for protein-protein interactions interfere with the proapoptotic function of cytochrome c
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity
The natural product fumagillin exhibits potent antiproliferative and antiangiogenic properties. The semisynthetic analog PPI-2458, [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-[(2R)-1-amino-3-methyl-1-oxobutan-2-yl]carbamate, demonstrates rapid inactivation of its molecular target, methionine aminopeptidase-2 (MetAP2), and good efficacy in several rodent models of cancer and inflammation with oral dosing despite low apparent oral bioavailability. To probe the basis of its in vivo efficacy, the metabolism of PPI-2458 was studied in detail. Reaction phenotyping identified CYP3A4/5 as the major source of metabolism in humans. Six metabolites were isolated from liver microsomes and characterized by mass spectrometry and nuclear resonance spectroscopy, and their structures were confirmed by chemical synthesis. The synthetic metabolites showed correlated inhibition of MetAP2 enzymatic activity and vascular endothelial cell growth. In an ex vivo experiment, MetAP2 inhibition in white blood cells, thymus, and lymph nodes in rats after single dosing with PPI-2458 and the isolated metabolites was found to correlate with the in vitro activity of the individual species. In a phase 1 clinical study, PPI-2458 was administered to patients with non-Hodgkin lymphoma. At 15 mg administered orally every other day, MetAP2 in whole blood was 80% inactivated for up to 48 hours, although the exposure of the parent compound was only ∼10% that of the summed cytochrome P450 metabolites. Taken together, the data confirm the participation of active metabolites in the in vivo efficacy of PPI-2458. The structures define a metabolic pathway for PPI-2458 that is distinct from that of TNP-470 ([(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-(2-chloroacetyl)carbamate). The high level of MetAP2 inhibition achieved in vivo supports the value of fumagillin-derived therapeutics for angiogenic diseases
Metabolites of PPI-2458, a Selective, Irreversible Inhibitor of Methionine Aminopeptidase-2: Structure Determination and In Vivo Activity
Orally Active Fumagillin Analogues: Transformations of a Reactive Warhead in the Gastric Environment
Semisynthetic
analogues of fumagillin, <b>1</b>, inhibit methionine aminopeptidase-2
(MetAP2) and have entered the clinic for the treatment of cancer.
An optimized fumagillin analogue, <b>3</b> (PPI-2458), was found
to be orally active, despite containing a spiroepoxide function that
formed a covalent linkage to the target protein. In aqueous acid, <b>3</b> underwent ring-opening addition of water and HCl, leading
to four products, <b>4–7</b>, which were characterized
in detail. The chlorohydrin, but not the diol, products inhibited
MetAP2 under weakly basic conditions, suggesting reversion to epoxide
as a step in the mechanism. In agreement, chlorohydrin <b>6</b> was shown to revert rapidly to <b>3</b> in rat plasma. In
an ex vivo assay, rats treated with purified acid degradants demonstrated
inhibition of MetAP2 that correlated with the biochemical activity
of the compounds. Taken together, the results indicate that degradation
of the parent compound was compensated by the formation of active
equivalents leading to a pharmacologically useful level of MetAP2
inhibition